Incyte | INCY - Operating Expenses


Incyte reported $973.64M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agenus USD -221.22M 241.03M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 359.47M 3.28M Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 15.77B 2.4B Jun/2026
Moderna USD 960M 817M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026